Hennigsdorf/Berlin (Germany), October 13, 2022 – Adrenomed AG, the vascular integrity company, today announced its participation in upcoming industry and investor conferences. The Adrenomed management
Hennigsdorf/Berlin (Germany), July 12, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of David Germonpré as Chief Financial Officer (CFO) of
“A phenomenal breakthrough is taking shape” An interview with Dr. Rainer Strohmenger, Managing Partner at Wellington Partners (Original interview in German)
Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options.
The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity, to treat life-threatening conditions associated with increased vascular leakage, congestion and shock. Our current lead indications are sepsis and septic shock.
We translate the concept of precision medicine into acute care. Our biomarker-guided approach enables us to identify the patients with loss of vascular integrity as an underlying pathophysiological disease mechanism and to treat patients that will most likely benefit from Adrecizumab therapy.
Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets.
Adrenomed is based in Hennigsdorf near Berlin, Germany.
Adrenomed was established in 2009 after the successful trade sale of the B·R·A·H·M·S AG to Thermo Fisher. The co-founders and executive managers of the B·R·A·H·M·S AG were Dr. Andreas Bergmann, who serves today as CSO of Adrenomed; also Dr. Bernd Wegener and Dr. Metod Miklus, who today are members of Adrenomed’s Supervisory Board. At B·R·A·H·M·S AG they changed the standard of care in sepsis by developing Procalcitonin (B·R·A·H·M·S PCTTM), the diagnostic gold standard sepsis biomarker.
The extensive in-depth work in sepsis, diagnostics and drug development led to well-established contacts with key opinion leaders worldwide in cardiovascular disease and sepsis that support Adrenomed’s clinical research.
Dr. Richard Jones
Chief Executive Officer (CEO)
Dr. Richard Jones, Chief Executive Officer (CEO) of Adrenomed, provides over 25 years of experience in the pharmaceutical and biotech industry with a strong record of achievements in business, clinical development and commercialization. Before joining Adrenomed in March 2022, Dr. Jones served as CEO of Fusion Antibodies Plc. Previously, he was CEO for several UK and European private companies as well as SVP, Head of Europe for a US based public company. Also, he gained expertise at Novartis and GSK as VP, Medicines Commercialization Leader, Global Haematology at both companies.
Dr. Andreas Bergmann
Chief Scientific Officer (CSO)
Dr. Andreas Bergmann, co-founder and Chief Scientific Officer (CSO) of Adrenomed and CEO of sphingotec GmbH and 4TEEN4 Pharmaceuticals GmbH, has deep knowledge and experience with the disease biology and diagnosis of sepsis. As inventor of more than 100 patents and co-founder & former executive manager of B·R·A·H·M·S AG, he helped to change the standard of care in sepsis by developing Procalcitonin, the diagnostic gold standard sepsis biomarker.
David Germonpré, MSc/Executive MBA
Chief Financial Officer (CFO)
David Germonpré, Chief Financial Officer (CFO), has over 15 years of experience as finance leader and strategist. Before joining Adrenomed in July 2022, Mr. Germonpré was Partner at MTIP, a Switzerland-based health-tech growth capital investor. Previously, for the Gemma Frisius Fund he invested in spinouts from Belgium’s KU Leuven. Between 2009 and 2013 David advised the Government of Flanders on its VC and PE programs. Prior to that he worked as investment banker at Dexia Bank, executing M&As and IPOs of big corporates.
Dr. Joachim Struck
Head of Research & Development
Dr. Joachim Struck is co-founder of Adrenomed and serves as Head of R&D since 2013. Before joining Adrenomed, he started his industrial career in 1991 at Henning Berlin GmbH (later B·R·A·H·M·S AG and Thermo Fisher Scientific). There, he developed several immunoassays and was responsible for discovery and clinical profiling of novel biomarkers as well as IP development. He is co-inventor of more than 50 patent families and is co-author of more than 200 peer-reviewed scientific publications.
Dr. Erich Schlick (Chairman)
Independent management consultant with over 40 years of experience in the pharma industry
Dr. Priyanka Belawat
Investment Advisor at HBM Partners
Dr. Ute Kilger
Partner at Boehmert & Boehmert
Dr. Metod Miklus
CEO of ExpoCapital GmbH and co-founder of B·R·A·H·M·S AG
Dr. Gerald Moeller
Independent management consultant, co-founder and former CEO of Adrenomed
Dr. Rainer Strohmenger
Managing Partner at Wellington Partners
Dr. Bernd Wegener
Co-founder of Adrenomed with over 35 years of management experience in the diagnostic and pharmaceutical industry
Adrenomed is dedicated to saving the lives of critically ill patients by translating the concept of personalized medicine to acute care. We are targeting Adrenomedullin, a peptide hormone with protective effects on endothelial barrier integrity. With a biomarker guided approach utilizing the target Adrenomedullin for patient selection, Adrenomed is developing a unique and holistic approach to rescue vascular integrity in life-threatening conditions such as sepsis and septic shock.
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity.
Suitability of using Adrecizumab to treat loss of vascular integrity is based on evidence obtained in multiple preclinical intensive care-like vascular integrity models with Adrecizumab applied on top of mimicked human standard of care treatment (e.g. fluids, vasopressors).
Adrecizumab treatment significantly improves all clinically relevant endpoints such as reduction of vascular leakage and vasopressor demand, stabilization of the circulation, normalization of fluid balance and kidney function. In preclinical septic shock models, Adrecizumab reduced the mortality by 50% (Intens Care Med Exp, 2013; Intens Care Med, 2013; Shock, 2018).
Furthermore, based on analyses of blood samples from well-defined patients, Adrenomedullin was reported as a therapeutic target and biomarker (bio-ADM®) for vascular integrity in several peer-reviewed scientific articles (Crit Care Med, 2020; Crit Care, 2018; Shock, 2018).
The recently marketed Adrenomedullin assay (sphingotest® bio-ADM®) allows the identification of patients suffering from loss of vascular integrity and will enable physicians to specifically treat these people by using Adrecizumab.
The lead candidate Adrecizumab is ready for a pivotal trial. In the AdrenOSS-2 (proof-of-concept phase II trial in septic shock) Adrecizumab demonstrated a favorable safety profile, was well tolerated and showed improved organ function and survival compared to placebo.
The monoclonal antibody Adrecizumab, presented a favorable safety profile in septic shock patients. Thereby meeting the primary trial objective. An improvement of organ function and a subsequent reduction of mortality has been observed.
A pre-specified biomarker analysis illustrated that treatment with Adrecizumab after ICU admission resulted in a rapid and sustained improvement of systemic organ function (SOFA score). Subsequently, the relative mortality was reduced by more than 30% after day 28. The positive effect on survival persisted over 90 days.
For further information please see the following article.
Results of Phase I trials evaluating Adrecizumab safety and tolerability
Vascular integrity – fundamental for human health
Regulation of vascular integrity is a fundamental process for human physiology and pathology. The vascular endothelium is the essential organ for the function of blood vessels in the human body. It is a cell monolayer that forms an essential and selective barrier between the blood vessels and the tissue compartment. The vascular endothelium actively maintains more than 100,000 kilometers of blood vessels.
Conditions that are most threatening to life, such as sepsis, septic shock, and acute heart failure, are driven by severe impairment of the vascular endothelial barrier presenting in porous, leaky blood vessels and resulting in tissue congestion and edema. Ultimately, the rapid fall in blood pressure and diminished oxygen supply to organs leads to multiple organ failure and death.
Adrenomedullin (ADM) – key regulator of vascular integrity
Since its discovery in 1993, the vasoprotective hormone Adrenomedullin has attracted a great deal of interest as a multifunctional regulator of the vascular system.
In the circulation, Adrenomedullin directly tightens the gaps between endothelial cells, subsequently preventing vascular leakage.
Adrenomedullin (bio-ADM®) was validated as therapeutic target and biomarker as reported in several scientific publications. Rising bio-ADM® values in patients’ blood samples clearly indicate a worsening of vascular integrity independent from inflammation or any other comorbidity, reflecting the patients need for a targeted therapy addressing this pathophysiology.
Sepsis & Septic Shock
Every year, millions of people around the world are affected by sepsis. In the US, sepsis contributes to between one third and half of deaths of hospitalized people, making it the number one cause of death in hospitals (). The annual cost of treating sepsis patients amounts to US$24 billion (Crit Care Med, 2018) in the US alone.
Sepsis has been defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (JAMA, 2016). This means that the body’s systemic immune reaction to an infecting pathogen gets out of control and starts affecting tissues and organs. Alongside these inflammatory responses, different regulatory systems such as cardio-vascular, metabolic and coagulation are affected.
A central driver of the pathogenesis of sepsis is the increasing loss of endothelial barrier function. In other words: The loss of vascular integrity. This leads to an uncontrolled leakage of fluid, proteins and cells into the surrounding tissue.
Patients suffer from a rapid drop in blood pressure (hypotension) and strong abnormalities in circulatory, cellular, and metabolic function. The reduced blood pressure, which further limits oxygen supply to organs (hypoperfusion), contributes to the development of multi-organ failure and death.
The current standard of care for septic shock patients is limited to anti-infectives, administration of vasopressors, fluids and supportive care.
With a biomarker-guided approach utilizing Adrenomedullin as a diagnostic marker and therapeutic target, Adrecizumab addresses the loss of vascular integrity to reduce vascular leakage, restore hemodynamic stability and consequently improve organ function and reduce mortality.
In COVID-19 and sepsis, a common disease mechanism is the compromised endothelial barrier with an uncontrolled permeability.
SARS-CoV-2 replicates in endothelial cells and leads to a breakdown of the endothelium via inflammatory pathways. This subsequently results in vascular leakage and severe impairment of organ function (Nat Rev Immunol, 2020; Nat Rev Immunol, 2021). High adrenomedullin levels indicating loss of vascular integrity are associated with worse outcomes and increased mortality in COVID-19 patients (J Clin Med, 2021).
While current therapeutic approaches to treat COVID-19 patients are antivirals or anti-inflammatory therapies, Adrecizumab addresses the endothelial barrier to restore vascular integrity. Treatment with Adrecizumab aims to reduce vascular leakage, improve organ function and reduce mortality.
At the beginning of the pandemic, the University Medical Center Hamburg-Eppendorf (UKE) in Hamburg, Germany, conducted a case series in critically ill COVID-19 patients with promising results (Biomolecules, 2020). Following this, the UKE is initiating and conducting a multicenter Phase II clinical trial to evaluate Adrecizumab in hospitalized patients with moderate to severe COVID-19 (ClinicalTrials.gov Identifier: NCT05156671). The clinical trial and the manufacturing of Adrecizumab are supported by funds from the German Federal Ministry of Education and Research (BMBF).
Hennigsdorf/Berlin (Germany), October 13, 2022 – Adrenomed AG, the vascular integrity company, today announced its participation in upcoming industry and investor conferences. The Adrenomed management team will be available for meetings to present and discuss the plans for its global
Hennigsdorf/Berlin (Germany), July 12, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of David Germonpré as Chief Financial Officer (CFO) of Adrenomed, effective July 11, 2022. David Germonpré has over 15 years experience as finance leader
Hennigsdorf/Berlin (Germany), June 23, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. med. Steffen Stürzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022. Dr. Stürzebecher is a board-certified pharmacologist with extensive
“A phenomenal breakthrough is taking shape” An interview with Dr. Rainer Strohmenger, Managing Partner at Wellington Partners (Original interview in German)
Article in Pink Sheet’s Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial
by Ian Schofield Executive Summary RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found nolinks between the mRNA vaccines and autoimmune hepatitis. Read the full article here.
Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden
Andreas Bergman, CSO and Frauke Hein, CBO were interviewed by Maike Telgheder from Handelsblatt. Check out the article (German only) here: Link to Handelsblatt article
In March, Adrenomed will be attending the 41st International Symposium on Intensive Care & Emergency Medicine, Brussels, Belgium. Conference dates: 22 – 25 March 2022 Additionally, Adrenomed will participate in BIO-Europe Spring (digital) Conference dates: 28 – 31 March 2022
Adrenomed will be attending J.P. Morgan 40th Annual Healthcare Conference 2022! Join us for #HealthcarePartneringWeek! You are welcome to contact Dr. Frauke Hein, Chief Business Officer of Adrenomed, at BD@adrenomed.com to arrange a meeting, where we’ll discuss partnership, collaboration opportunities
Weimar Sepsis Update, Sep 8-10, 2021 Adrenomed will co-host the symposium “Precision Medicine in Septic Organ Failure: Biomarker-guided Diagnosis and Therapy” on September 9th, 12:00-13:30 CEST Chair: Prof. Dr. med. Markus Weigand Link to the Conference
Adrenomed – a clinical-stage biopharmaceutical company, located in the Berlin area.
We are a multi-disciplinary, international team committed to pioneering the development of precision medicine for critically ill patients with limited treatment options.
We are always looking for talented, dedicated professionals to join our team. Check our current job listings to find out more.
Applications are always welcome, even if we do not have any listed openings. Please submit a resume and cover letter to email@example.com.